Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",body mass,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,7,,CMO:0001400,maximum body weight loss to initial body weight ratio,,,,0,%,0.0,0.0,MMO:0000016,body weighing method,,0.0,from before p.i.,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68728,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",body mass,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,8,,CMO:0001400,maximum body weight loss to initial body weight ratio,,,,0,%,0.0,0.0,MMO:0000016,body weighing method,,0.0,from before p.i.,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68725,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",body mass,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001400,maximum body weight loss to initial body weight ratio,,,,0,%,0.0,0.0,MMO:0000016,body weighing method,,0.0,from before p.i.,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68723,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",body mass,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001400,maximum body weight loss to initial body weight ratio,,,,1.2,%,1.1384,3.6,MMO:0000016,body weighing method,,0.0,from before p.i.,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68720,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,1,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68729,myelin oligodendrocyte glycoprotein (20 ug) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,7,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68733,myelin oligodendrocyte glycoprotein (200 ul) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,8,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,37.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68732,myelin oligodendrocyte glycoprotein (200 ul) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,3,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68721,myelin oligodendrocyte glycoprotein (20 ug) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,6,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,13.3,d,2.6,6.3687,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68731,myelin oligodendrocyte glycoprotein (200 ul) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,1,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,3,d,0.0,0.0,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68730,myelin oligodendrocyte glycoprotein (200 ul) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,1,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,23,d,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68727,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,3,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,14.7,d,1.4434,2.5,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68719,myelin oligodendrocyte glycoprotein (20 ug) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",total life span,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,8,,CMO:0001024,percentage of deaths in a study population during a period of time,,,,12.5,%,,,MMO:0000344,necropsy,whole animal,0.0,visual assessment,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68737,myelin oligodendrocyte glycoprotein (200 ul) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",total life span,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,7,,CMO:0001024,percentage of deaths in a study population during a period of time,,,,0,%,,,MMO:0000344,necropsy,whole animal,0.0,visual assessment,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68736,myelin oligodendrocyte glycoprotein (200 ul) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,75,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68735,myelin oligodendrocyte glycoprotein (200 ul) 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,14.3,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68734,myelin oligodendrocyte glycoprotein (200 ul) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,14,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68726,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68724,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68722,myelin oligodendrocyte glycoprotein (20 ug) 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68718,myelin oligodendrocyte glycoprotein (20 ug)